# EDGAR Filing Document

**Accession Number:** 0002085726
**File Stem:** 0002085726-25-000004
**Filing Date:** 2025-10
**Character Count:** 21446
**Document Hash:** 2838d9a17dd6f1651365e1b105330b2f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0002085726-25-000004.hdr.sgml**: 20251016

**ACCESSION NUMBER**: 0002085726-25-000004

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20251016

**DATE AS OF CHANGE**: 20251016

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** LEAP THERAPEUTICS, INC.
- **CENTRAL INDEX KEY:** 0001509745
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 274412575
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-90188
- **FILM NUMBER:** 251398772

**BUSINESS ADDRESS:**
- **STREET 1:** 47 THORNDIKE STREET
- **STREET 2:** SUITE B1-1
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142
- **BUSINESS PHONE:** 617 252 4343

**MAIL ADDRESS:**
- **STREET 1:** 47 THORNDIKE STREET
- **STREET 2:** SUITE B1-1
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Dekkun Corp
- **DATE OF NAME CHANGE:** 20110107
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Winklevoss Capital Fund, LLC
- **CENTRAL INDEX KEY:** 0002085726

**ORGANIZATION NAME:**
- **EIN:** 454617407
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**BUSINESS ADDRESS:**
- **STREET 1:** FARMERS BANK BUILDING
- **STREET 2:** 301 N. MARKET STREET, SUITE 1463
- **CITY:** WILIMNGTON
- **STATE:** DE
- **ZIP:** 19801
- **BUSINESS PHONE:** (646) 751-4444

**MAIL ADDRESS:**
- **STREET 1:** FARMERS BANK BUILDING
- **STREET 2:** 301 N. MARKET STREET, SUITE 1463
- **CITY:** WILIMNGTON
- **STATE:** DE
- **ZIP:** 19801

## Exhibit 99.1

**<u>Exhibit 99.1</u>**

**JOINT FILING AGREEMENT**

This Joint Filing Agreement, dated as of October 14, 2025, is by and among Winklevoss Capital Fund, LLC, Winklevoss Treasury Investments, LLC, Winklevoss Capital Management, LLC, Tyler H. Winklevoss, and Cameron H. Winklevoss. (collectively, the "Filers").

Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13D and/or 13G with respect to the shares of common stock, with a nominal value of $0.001 per share, of Leap Therapeutics, Inc. beneficially owned by them from time to time.

Pursuant to and in accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the Filers hereby agree to file a single statement on Schedule 13D and/or 13G (and any amendments thereto) on behalf of each of the Filers, and hereby further agree to file this Joint Filing Agreement as an exhibit to such statement, as required by such rule.

This Joint Filing Agreement may be terminated by any of the Filers upon written notice or such lesser period of notice as the Filers may mutually agree.

Executed and delivered as of the date first above written.

---

| | |
|:---|:---|
| **Winklevoss Capital Fund, LLC** | **Winklevoss Treasury Investments, LLC** |
| By: Winklevoss Capital Management LLC<br> Its: Manager<br>By: <u>/s/ Cameron H. Winklevoss</u> | <br>By: <u>/s/ William McEvoy</u>  |
| Name: Cameron H. Winklevoss  | Name: William McEvoy  |
| Title: Manager | Title: Manager |
| **Winklevoss Capital Management, LLC** | **Tyler H. Winklevoss** |
| <br>By: <u>/s/ Cameron Winklevoss</u>  | <br>By: <u>/s/ Tyler H. Winklevoss</u>  |
| Name: Cameron Winklevoss | Name: Tyler H. Winklevoss |
| Title: Manager |  |
| **Cameron H. Winklevoss** |  |
| <br>By: <u>/s/ Cameron Winklevoss</u>  |  |
| Name: Cameron H. Winklevoss |  |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**Leap Therapeutics, Inc.**

*(Name of Issuer)*

**Common Stock, par value $0.001 per share**

*(Title of Class of Securities)*

**52187K200**

*(CUSIP Number)*

**William McEvoy**<br>Winklevoss Treasury Investments, LLC<br>301 N Market Street Suite 1463<br>Wilmington DE 19801<br>646-751-4444

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**10/08/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **52187K200** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Winklevoss Capital Fund, LLC** | Name of reporting person<br>**Winklevoss Capital Fund, LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**12084463.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**12084463.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**12084463.00** | Aggregate amount beneficially owned by each reporting person<br>**12084463.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**19.9%** | Percent of class represented by amount in Row (11)<br>**19.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

| **CUSIP No.** | **52187K200** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Winklevoss Treasury Investments, LLC** | Name of reporting person<br>**Winklevoss Treasury Investments, LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**12084463.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**12084463.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**12084463.00** | Aggregate amount beneficially owned by each reporting person<br>**12084463.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**19.9%** | Percent of class represented by amount in Row (11)<br>**19.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

| **CUSIP No.** | **52187K200** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Winklevoss Capital Management, LLC** | Name of reporting person<br>**Winklevoss Capital Management, LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**12084463.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**12084463.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**12084463.00** | Aggregate amount beneficially owned by each reporting person<br>**12084463.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**19.9%** | Percent of class represented by amount in Row (11)<br>**19.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

| **CUSIP No.** | **52187K200** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Tyler Howard Winklevoss** | Name of reporting person<br>**Tyler Howard Winklevoss** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**12084463.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**12084463.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**12084463.00** | Aggregate amount beneficially owned by each reporting person<br>**12084463.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**19.9%** | Percent of class represented by amount in Row (11)<br>**19.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

| **CUSIP No.** | **52187K200** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Cameron Howard Winklevoss** | Name of reporting person<br>**Cameron Howard Winklevoss** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**12084463.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**12084463.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**12084463.00** | Aggregate amount beneficially owned by each reporting person<br>**12084463.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**19.9%** | Percent of class represented by amount in Row (11)<br>**19.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.001 per share

**(b) Name of Issuer:**
Leap Therapeutics, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
47 Thorndike Street, Suite B1-1, Cambridge, MA, 02141

**Item 4. Purpose of Transaction**

The information set forth in or incorporated by reference in Item 3 of this Schedule 13D is hereby incorporated by reference in its entirety into this Item 4.

In connection with the Private Placement and pursuant to WTI's right to nominate two Investor Designees pursuant to the Lead Investor Agreement, WTI intends to nominate two Investor Designees, one of whom will also serve as Chairman of the Board, effective upon appointment. Upon their appointment to the Board, the Investor Designees shall be entitled to insurance coverage applicable to directors and officers of the Issuer. In the event that a vacancy is created at any time by the death, disability, retirement, disqualification, resignation or removal (with or without cause) of the Investor Designee, WTI shall have the right to designate a replacement to fill such vacancy and the Issuer shall cause such vacancy to be filled by the replacement so designated and the Board shall promptly elect such designee to the Board.

The Reporting Persons acquired the Common Stock described in this 13D for investment purposes and intend to review their investments in the Issuer on a continuing basis. Depending on various factors, including, without limitation, the Issuer's financial position and strategic direction, actions taken by the Issuer's management and the Board, price levels of the Common Stock, other investment opportunities available to the Reporting Persons, conditions in the securities markets and general economic and industry conditions, the Reporting Persons may from time to time and at any time in the future take or engage in various plans, actions or transactions with respect to the investment in the Issuer as they deem appropriate, including, without limitation, exercising their Common Warrants or Pre-Funded Warrants for shares of Common Stock, purchasing additional shares of Common Stock, disposing of shares of Common Stock, acquiring other financial instruments that are based upon or relate to the value of the Common Stock, selling or obtaining financing on some or all of their beneficial or economic holdings, engaging in hedging or similar transactions with respect to securities that are based upon or relate to the value of the Common Stock, or proposing or considering, or changing their intention with respect to, one or more of the actions described in subsections (a) through (j) of Item 4 of Schedule 13D.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The Reporting Persons each beneficially own an aggregate of 12,084,463 shares of Common Stock (including 3,800,702 shares of Common Stock issuable upon exercise of Pre-Funded Warrants or Common Warrants) (the "Subject Shares") which represent approximately 19.99% of the outstanding shares of Common Stock, based on 56,651,840 shares of Common Stock outstanding as of October 8, 2025, and assumes the exercise of certain of the Pre-Funded Warrants or Common Warrants in an amount not to exceed the Beneficial Ownership Limitation.

The Reporting Persons disclaim beneficial ownership of the shares of Common Stock owned by Howard Winklevoss, the father of Tyler Winklevoss and Cameron Winklevoss.

Each of the Reporting Persons may be deemed to have the shared power to vote or direct the vote of (and the shared power to dispose or direct the disposition of) all of the Subject Shares.

**(b)**
See Items 7-11 of the cover pages and Item 5(a) above.

**(c)**
Except as set forth in Item 3 of the Schedule 13D, no transactions in the shares of Common Stock have been effected by the Reporting Persons in the past sixty (60) days.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

The information set forth in or incorporated by reference in Items 3, 4, and 5 of this Schedule 13D is hereby incorporated by reference in its entirety into this Item 6.

The Reporting Persons may, from time to time, enter into and dispose of swaps, options or other derivative transactions with one or more counterparties that are based upon the value of the Common Stock, which transactions may be significant in amount. The profit, loss and/or return on such contracts may be wholly or partially dependent on the market value of the Common Stock.

On October 16, 2025, the Reporting Persons entered into a Joint Filing Agreement in which the Reporting Persons agreed to the joint filing on behalf of each of them of statements on Schedule 13D with respect to the securities of the Issuer to the extent required by applicable law. The Joint Filing Agreement is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Except as set forth herein, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among the persons named in Item 2 hereof and between such persons and any person with respect to any securities of the Issuer, including any class of the Issuer's securities used as a reference security, in connection with any of the following: call options, put options, security-based swaps or any other derivative securities, transfer or voting of any of the securities, finder's fees, joint ventures, loan or option arrangements, guarantees of profits, division of profits or loss, or the giving or withholding of proxies.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Winklevoss Capital Fund, LLC

**Signature:** /s/ Cameron H. Winklevoss

**Name/Title:** By Winklevoss Capital Management, LLC, Its Manager, By Cameron H. Winklevoss, Manager

**Date:** 10/16/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Winklevoss Treasury Investments, LLC

**Signature:** /s/ William McEvoy

**Name/Title:** By William McEvoy, Manager

**Date:** 10/16/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Winklevoss Capital Management, LLC

**Signature:** /s/ Cameron H. Winklevoss

**Name/Title:** By Cameron H. Winklevoss, Manager

**Date:** 10/16/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Tyler Howard Winklevoss

**Signature:** /s/ Tyler H. Winklevoss

**Name/Title:** Tyler H. Winklevoss

**Date:** 10/16/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Cameron Howard Winklevoss

**Signature:** /s/ Cameron H. Winklevoss

**Name/Title:** Cameron H. Winklevoss

**Date:** 10/16/2025